866-997-4948(US-Canada Toll Free)

Alzheimers Disease Global Clinical Trials Review, H1, 2017

Published By :

GlobalData

Published Date : Mar 2017

Category :

Diseases & Conditions

No. of Pages : 35 Pages

Alzheimer's Disease Global Clinical Trials Review, H1, 2017

Summary

GlobalData's clinical trial report, Alzheimer's Disease Global Clinical Trials Review, H1, 2017" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 20
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 27
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials 31
Prominent Drugs 32
Latest Clinical Trials News on Alzheimer's Disease 33
Mar 20, 2017: Corium Reports Positive Progress in Pilot Bioequivalence Study of Once-Weekly Corplex Donepezil Patch 33
Mar 16, 2017: QR Pharma Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference 33
Mar 15, 2017: Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer's Disease 33
Mar 10, 2017: Nature Cell Started Commercial Clinical Trials Phase I and II ASTROSTEM, Stem Cell Drug for Alzheimers Disease Treatment in US 34
Mar 08, 2017: TGA Regulatory Approval Received for Alzheimers Phase II Trial 34
Mar 08, 2017: Diabetes drug shows promise for safely treating, detecting Alzheimers disease 35
Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease 35
Mar 06, 2017: BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer 35
Mar 06, 2017: MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease 36
Mar 01, 2017: Luye Pharma Group: Announcement Approval To Commence Clinical Trials For Rivastigmine Multi-Day Transdermal Patch In Germany 36
Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer's Therapy Crenezumab 36
Feb 28, 2017: Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimers 37
Feb 19, 2017: BIIB076 Moves into Phase 1 for Alzheimer Disease 37
Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy 38
Feb 14, 2017: Cantabio Pharmaceuticals to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimers Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease 38
Feb 13, 2017: Alzheon to Present New Clinical Data and Analyses for ALZ-801 and Its Active Molecule Tramiprosate at the 13th International Conference on Alzheimers and Parkinsons Diseases 39
Feb 09, 2017: Xanamem research published in prestigious medical journal 39
Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment 39
Jan 26, 2017: New drug SAK3 may offer hope to Alzheimer's disease patients 40
Jan 25, 2017: ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimers and Parkinsons Diseases in Vienna, Austria 40
Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy 40
Jan 25, 2017: Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience 41
Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board 42
Jan 10, 2017: UK Regulatory Approval for Alzheimer's Disease Clinical Trial - XanADu 42
Jan 09, 2017: Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimers disease patients 42
Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimers Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers 43
Jan 03, 2017: FDA Approval to Commence Alzheimers Disease Clinical Trial 43
Dec 27, 2016: Investigational new drug for Alzheimer's scheduled for first study in humans 43
Clinical Trial Profile Snapshots 45
Appendix 831
Abbreviations 831
Definitions 831
Research Methodology 832
Secondary Research 832
About GlobalData 833
Contact Us 833
Source 833

List of Tables
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2017* 7
Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 21
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2017* 24
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 13
Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 15
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 20
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2017* 24
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 25
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29
Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
GlobalData Methodology 832

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *